Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models

Yu Hsiang Hsu, Cheng Ying Wu, Chung Hsi Hsing, Wei Ting Lai, Li Wha Wu, Ming Shi Chang

研究成果: Article同行評審

14 引文 斯高帕斯(Scopus)

摘要

Interleukin (IL)-20 is a proinflammatory cytokine in the IL-10 family. IL-20 is associated with tumor promotion in the pathogenesis of oral, bladder, and breast cancer. However, little is known about the role of IL-20 in prostate cancer. We hypothesize that IL-20 promotes the growth of prostate cancer cells. Immunohistochemical staining showed that IL-20 and its receptors were expressed in human PC-3 and LNCaP prostate cancer cell lines and in prostate tumor tissue from 40 patients. In vitro, IL-20 upregulated N-cadherin, STAT3, vimentin, fibronectin, RANKL, cathepsin G, and cathepsin K, and increased the migration and colony formation of prostate cancer cells via activated p38, ERK1/2, AKT, and NF-κB signals in PC-3 cells. We investigated the effects of anti-IL-20 monoclonal antibody 7E on prostate tumor growth in vivo using SCID mouse subcutaneous and intratibial xenograft tumor models. In vivo, 7E reduced tumor growth, suppressed tumor-mediated osteolysis, and protected bone mineral density after intratibial injection of prostate cancer cells. We conclude that IL-20 is involved in the cell migration, colony formation, and tumor-induced osteolysis of prostate cancer. Therefore, IL-20 might be a novel target for treating prostate cancer.

原文English
文章編號e0139871
期刊PloS one
10
發行號10
DOIs
出版狀態Published - 2015 10月 6

All Science Journal Classification (ASJC) codes

  • 多學科

指紋

深入研究「Anti-IL-20 monoclonal antibody suppresses prostate cancer growth and bone osteolysis in murine models」主題。共同形成了獨特的指紋。

引用此